![]() ![]() 2–5 The ATLANTIS study was initially designed to evaluate the efficacy and safety of intravenous tPA in patients with acute stroke who could be treated within 6 hours of symptom onset.Īfter December 1993, the ATLANTIS study design was changed to enroll patients within 5 hours of symptom onset because of safety concerns in patients enrolled between 5 and 6 hours. Three subsequent large trials, the European Cooperative Acute Stroke Study (ECASS), ECASS II, and the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study, failed to document clear benefits of intravenous tPA administered beyond 3 hours of stroke onset. 1 In the NINDS study, patients were treated within 3 hours of symptom onset. Only the National Institute of Neurologic Disorders (NINDS) trial has clearly demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) for treatment of acute stroke. Customer Service and Ordering Information.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes. ![]() Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
June 2023
Categories |